Larsdotter S, Nostell K, von Euler H
University Animal Hospital, Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden.
Department of Clinical Sciences, Division of Large Animals, Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden.
Vet J. 2015 Aug;205(2):313-6. doi: 10.1016/j.tvjl.2015.01.019. Epub 2015 Jan 28.
Serum thymidine kinase (sTK) activity is a tumour marker used as a prognostic indicator for lymphoma in humans, dogs and cats. The aim of this study was to evaluate the clinical utility of sTK as a biomarker for lymphoma in horses. Serum samples were collected from clinically normal horses (n = 37), horses with lymphoma (n = 23), horses with non-haematopoietic neoplasia (n = 9) and horses with inflammatory disease (n = 14). sTK was measured using a radioenzyme assay. A reference cut-off value of <2.7 U/L (mean + 2 standard deviations, SDs) was established using data from clinically normal horses. sTK activity (mean ± SD) was 26.3 ± 91.5 U/L (range 0.8-443 U/L) for horses with lymphoma, 2.3 ± 1.4 U/L (range 0.6-5.7 U/L) for horses with non-haematopoietic neoplasia and 1.5 ± 0.6 U/L (range 0.6-2.8 U/L) for horses with inflammatory disease. Horses with lymphoma had significantly higher sTK activity than horses without clinical signs of disease (P <0.01), horses with inflammatory disease (P <0.01) and horses with non-haematopoietic neoplasia (P <0.05). sTK activity is a potentially useful biomarker for equine lymphoma.
血清胸苷激酶（sTK）活性是一种肿瘤标志物，用作人类、犬类和猫类淋巴瘤的预后指标。本研究的目的是评估sTK作为马淋巴瘤生物标志物的临床实用性。从临床正常的马（n = 37）、患有淋巴瘤的马（n = 23）、患有非造血系统肿瘤的马（n = 9）和患有炎症性疾病的马（n = 14）采集血清样本。使用放射酶测定法测量sTK。利用临床正常马的数据建立了<2.7 U/L（平均值+2个标准差，SDs）的参考临界值。患有淋巴瘤的马的sTK活性（平均值±SD）为26.3±91.5 U/L（范围0.8 - 443 U/L），患有非造血系统肿瘤的马为2.3±1.4 U/L（范围0.6 - 5.7 U/L），患有炎症性疾病的马为1.5±0.6 U/L（范围0.6 - 2.8 U/L）。患有淋巴瘤的马的sTK活性显著高于无疾病临床症状的马（P <0.01）、患有炎症性疾病的马（P <0.01）和患有非造血系统肿瘤的马（P <0.05）。sTK活性是马淋巴瘤的一种潜在有用的生物标志物。
